Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Hisamitsu Pharmaceutical Co's average EBITDA Per Share Growth Rate was -9.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 20.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -1.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hisamitsu Pharmaceutical Co was 30.80% per year. The lowest was -20.90% per year. And the median was -1.30% per year.
Hisamitsu Pharmaceutical Co (FSE:4530) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Hisamitsu Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms
FSE:4530 vs AMPH, ESPR, NIKA: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.
Hisamitsu Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.50% mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a 3-Year EBITDA Growth Rate of 17.50% as of Nov. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hisamitsu Pharmaceutical Co and its competitors. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #286 out of 811 companies in the Drug Manufacturers industry, placing it in the top 35.3%.
Is Hisamitsu Pharmaceutical Co's 3-Year EBITDA Growth Rate too high?
Hisamitsu Pharmaceutical Co's current 3-Year EBITDA Growth Rate is 17.50%. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Hisamitsu Pharmaceutical Co's value of 17.50% is 98.9% above this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #286 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's 3-Year EBITDA Growth Rate compare to AMPH and ESPR?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #286 out of 811 companies for 3-Year EBITDA Growth Rate. This puts Hisamitsu Pharmaceutical Co in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Hisamitsu Pharmaceutical Co's value of 17.50% is 98.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current 3-Year EBITDA Growth Rate of 17.50% is 98.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current 3-Year EBITDA Growth Rate is 17.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current 3-Year EBITDA Growth Rate of 17.50%. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 17.50% and 98.9% above the Drug Manufacturers industry median of 8.80. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current 3-Year EBITDA Growth Rate is 17.50% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
3-Year EBITDA Growth Rate: 17.50%
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 98.9% above the Drug Manufacturers median (#286 of 811)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
